SecurAcath Study of Over 2000 Patients Shows Major Cost Savings Compared to Adhesives

LG Thin-Clients Feature Built-in RFID Capabilities Optimized for Use in Healthcare Facilities

Supporting its mission to help healthcare providers streamline operations and deliver exceptional patient care, LG Business Solutions USA introduced a new LG thin client...

Experien Group Acquired by Veranex

Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets.

Interrad Medical, a privately held medical device company, announces a new clinical data publication that shows an impressive decrease in material and catheter replacement costs with use of the SecurAcath Subcutaneous Catheter Securement device compared to an adhesive securement device.

The publication titled “Intravascular catheter migration: A cross-sectional and health-economic comparison of adhesive and subcutaneous engineered stabilisation devices for intravascular device securement,” by Dympna McParlan, et al., Belfast City Hospital, Belfast, Northern Ireland, was published in the Journal of Vascular Access in June 2019. The paper is a PICC securement study that compared one full year of Statlock use (1,111 patients) to one full year of SecurAcath Subcutaneous ESD (engineered stabilization device) use (1,139 patients). Average dwell time per patient was 6 months. There was a 5.9% catheter replacement rate with Statlock use compared to a 0% replacement with SecurAcath.

Cost savings due to decrease in catheter replacement was £17,952, Cost savings due to not changing out SecurAcath was £59,322 for a total savings of £77,274 annually.

McParlan states in the paper, “The introduction of subcutaneous ESDs has resulted in significant benefits for the patient, practitioner and the trust. This may have significant impact at a national level, indicating larger cost savings of over £8.8 million (€9.74/US$11.1 million) per year, simply by reducing catheter replacement from unintentional dislodgements and the frequent replacement of adhesive securements during each dressing change.”

“We are very excited this large comparative study data shows a significant cost savings with use of the SecurAcath,” commented Joe Goldberger, President and CEO of Interrad Medical. He added, “This important new data adds to the clinical evidence base that supports the fact that the SecurAcath provides improved catheter securement by reducing complications and cost of care.”

The SecurAcath is the only subcutaneous catheter securement device that lasts the life of the line and can dramatically decrease catheter dislodgement and migration, decrease catheter replacement costs, prevent therapy interruption, reduce catheter-related infections and other complications, and lower total cost of patient care.



Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.